For millions of people living with severe hyperlipidemia, the standard of care—statins and lifestyle changes—is often not enough. In some cases, genetic predispositions make cholesterol and triglyceride levels nearly impossible to manage with traditional pills, leaving patients at a heightened risk for premature cardiovascular disease. A new class of precision medicine is now attempting to close this gap by targeting the very instructions our cells employ to produce lipids.
Recent data from a phase 1 basket trial suggests that Zodasiran for cholesterol and triglyceride lowering represents a significant step forward in this effort. By utilizing RNA interference (RNAi), Zodasiran silences a specific protein called angiopoietin-like protein 3 (ANGPTL3), which normally acts as a brake on the body’s ability to clear fats from the bloodstream. When that brake is removed, the body can more efficiently process both low-density lipoprotein (LDL) cholesterol and triglycerides.
The “basket” design of the trial allowed researchers to test the drug across several different patient cohorts simultaneously, including those with mixed hyperlipidemia and those with homozygous familial hypercholesterolemia (HoFH)—a rare and dangerous genetic condition. The final report indicates that Zodasiran was generally well-tolerated and produced a marked reduction in lipid levels across these diverse groups, providing a potential lifeline for patients who have failed maximal-potency statin therapy.
The Science of Silencing ANGPTL3
To understand why Zodasiran is promising, it is helpful to look at the role of ANGPTL3. In a healthy system, this protein inhibits two key enzymes: lipoprotein lipase (LPL) and endothelial lipase (EL). These enzymes are essentially the “cleanup crew” of the cardiovascular system, breaking down triglycerides and helping to clear VLDL and LDL particles from the blood.
When ANGPTL3 levels are high, the cleanup crew is sidelined, leading to the accumulation of fats in the arteries. However, nature provides a clue: people with rare genetic mutations that cause a natural deficiency in ANGPTL3 often have exceptionally low cholesterol and triglyceride levels and a reduced risk of coronary artery disease. Zodasiran mimics this natural protection. As a GalNAc-conjugated siRNA, it is designed to travel directly to the liver, where it triggers the degradation of the messenger RNA (mRNA) responsible for producing the ANGPTL3 protein.
Unlike monoclonal antibodies that bind to the protein after it is already made, RNAi therapy stops the protein from being produced in the first place. This approach typically offers a more durable effect, potentially reducing the frequency of dosing for the patient.
Efficacy Across High-Risk Patient Groups
The phase 1 trial focused on safety and dosing, but the lipid-lowering effects were a central part of the findings. The drug demonstrated a broad ability to lower “awful” cholesterol and triglycerides, regardless of the patient’s specific type of lipid disorder.
For patients with mixed hyperlipidemia—those struggling with both high cholesterol and high triglycerides—Zodasiran showed a consistent ability to lower non-HDL cholesterol. This is particularly important because triglycerides are often more challenging to treat than LDL alone, and their elevation is independently linked to an increased risk of atherosclerotic cardiovascular disease (ASCVD).
The results were perhaps most striking in the homozygous familial hypercholesterolemia (HoFH) cohort. Patients with HoFH have severely limited LDL receptor function, meaning their bodies cannot clear LDL cholesterol through the usual pathways. Because Zodasiran works through an ANGPTL3-dependent pathway that does not rely on the LDL receptor, it can lower cholesterol in patients for whom almost every other drug is ineffective. This has been further explored in studies such as the Lancet Diabetes & Endocrinology research on HoFH treatments.
Comparing ANGPTL3 Targeting Strategies
Zodasiran is part of a larger movement toward ANGPTL3 inhibition. While several modalities exist, they differ significantly in how they interact with the body.
| Modality | Example | Mechanism | Typical Delivery |
|---|---|---|---|
| Monoclonal Antibody | Evinacumab | Binds and neutralizes the protein | Intravenous Infusion |
| Antisense Oligonucleotide | Vupanorsen | Degrades mRNA via RNase H | Subcutaneous Injection |
| siRNA (RNAi) | Zodasiran | Silences gene expression via RISC | Subcutaneous Injection |
Safety, Tolerability, and the Path Forward
One of the primary concerns with any new lipid-lowering agent is the potential for off-target effects or the risk of inducing hepatic steatosis (fatty liver). However, the phase 1 data for Zodasiran indicates a favorable safety profile. Most adverse events reported were mild to moderate and did not lead to a high rate of discontinuation.
The durability of the RNAi effect is a key advantage. Because the silencing of the ANGPTL3 gene lasts for several weeks or months, the burden of treatment is significantly lower than that of daily pills. This improves patient adherence, which is often a major hurdle in the long-term management of chronic hyperlipidemia.
As the drug moves into later-stage trials, the focus will shift from “can it lower lipids” to “does it prevent heart attacks and strokes.” The ultimate goal of Zodasiran for cholesterol and triglyceride lowering is to prove that these biochemical changes translate into a tangible increase in life expectancy and a decrease in cardiovascular events.
For those currently managing refractory hyperlipidemia, these results offer a glimpse of a future where “untreatable” cholesterol is a thing of the past. The shift toward transcriptomic therapies—medicine that edits the messages our genes send—is transforming the landscape of preventive cardiology.
Disclaimer: This article is for informational purposes only and does not constitute medical advice. Patients should consult with a healthcare provider before making any changes to their medication or treatment plan.
The next major milestone for Zodasiran will be the completion of larger, randomized phase 2 and 3 trials, which will further define the optimal dosing intervals and provide more robust data on long-term cardiovascular outcomes. Official updates on these trials are typically published in peer-reviewed journals such as The New England Journal of Medicine or Nature Medicine.
Do you have questions about the future of RNAi therapies or the management of high cholesterol? Share your thoughts in the comments or share this article with others who may find it helpful.
